dc.contributor.author |
Giovannoni, Gavin |
|
dc.contributor.author |
Boyko, Alexey |
|
dc.contributor.author |
Correale, Jorge |
|
dc.contributor.author |
Edan, Gilles |
|
dc.contributor.author |
Freedman, Mark S. |
|
dc.contributor.author |
Montalban, Xavier |
|
dc.contributor.author |
Rammohan, Kottil |
|
dc.contributor.author |
Stefoski, Dusan |
|
dc.contributor.author |
Yamout, Bassem |
|
dc.contributor.author |
Leist, Thomas |
|
dc.contributor.author |
Aydemir, Aida |
|
dc.contributor.author |
Borsi, Laszlo |
|
dc.contributor.author |
Verdun di Cantogno, Elisabetta |
|
dc.date.accessioned |
2023-12-12T13:55:36Z |
|
dc.date.available |
2023-12-12T13:55:36Z |
|
dc.date.issued |
2023-04-03 |
|
dc.identifier.citation |
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 May;29(6):719-730. doi: 10.1177/13524585231161494 |
es_ES |
dc.identifier.uri |
https://doi.org/10.1177/13524585231161494 |
|
dc.identifier.uri |
https://repositorio.fleni.org.ar/xmlui/handle/123456789/906 |
|
dc.description.abstract |
Background: CLASSIC-MS evaluated the long-term efficacy of cladribine tablets in patients with relapsing multiple sclerosis.
Objective: Report long-term mobility and disability beyond treatment courses received in CLARITY/CLARITY Extension.
Methods: This analysis represents CLASSIC-MS patients who participated in CLARITY with/without participation in CLARITY Extension, and received ⩾1 course of cladribine tablets or placebo (N = 435). Primary objective includes evaluation of long-term mobility (no wheelchair use in the 3 months prior to first visit in CLASSIC-MS and not bedridden at any time since last parent study dose (LPSD), i.e. Expanded Disability Status Scale (EDSS) score <7). Secondary objective includes long-term disability status (no use of an ambulatory device (EDSS < 6) at any time since LPSD).
Results: At CLASSIC-MS baseline, mean ± standard deviation EDSS score was 3.9 ± 2.1 and the median time since LPSD was 10.9 (range = 9.3-14.9) years. Cladribine tablets-exposed population: 90.6% (N = 394), including 160 patients who received a cumulative dose of 3.5 mg/kg over 2 years. Patients not using a wheelchair and not bedridden: exposed, 90.0%; unexposed, 77.8%. Patients with no use of an ambulatory device: exposed, 81.2%; unexposed, 75.6%.
Conclusion: With a median 10.9 years' follow-up after CLARITY/CLARITY Extension, findings suggest the sustained long-term mobility and disability benefits of cladribine tablets. |
es_ES |
dc.language.iso |
eng |
es_ES |
dc.publisher |
Sage |
es_ES |
dc.rights |
info:eu-repo/semantics/openAccess |
|
dc.subject |
Cladribine |
es_ES |
dc.subject |
Cladribina |
es_ES |
dc.subject |
Immunosuppressive Agents |
es_ES |
dc.subject |
Inmunosupresores |
es_ES |
dc.subject |
Multiple Sclerosis |
es_ES |
dc.subject |
Esclerosis Múltiple |
es_ES |
dc.subject |
Neoplasm Recurrence |
es_ES |
dc.subject |
Recurrencia de Neoplasia |
es_ES |
dc.title |
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study |
es_ES |
dc.type |
info:eu-repo/semantics/article |
es_ES |
dc.type |
info:eu-repo/semantics/publishedVersion |
|
dc.description.fil |
Fil: Correale, Jorge. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina. |
|
dc.relation.ispartofVOLUME |
29 |
|
dc.relation.ispartofNUMBER |
6 |
|
dc.relation.ispartofPAGINATION |
719-730 |
|
dc.relation.ispartofCOUNTRY |
Reino Unido |
|
dc.relation.ispartofCITY |
Londres |
|
dc.relation.ispartofTITLE |
Multiple sclerosis |
|
dc.relation.ispartofISSN |
1477-0970 |
|
dc.type.snrd |
info:ar-repo/semantics/artículo |
es_ES |